Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.
Our primary focus is the discovery and early development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
We have established partnerships with some of the world’s leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies
Sosei Heptares has approximately 161 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
We are now seeking a membrane protein biochemist to join the Biochemistry group at our research facility on Granta Park, Cambridge, UK, working on membrane protein biochemical characterisation to enable drug discovery efforts.
At Sosei Heptares we are equipped with state-of-the-art protein expression, purification, SPR, mass-spectrometry, crystallisation and cryoEM facilities. Applicants should have experience in the expression and purification of challenging membrane proteins destined for biochemical, biophysical and structural studies. Applicants with a proven track record of publications related to the expression, purification, and biochemical characterisation of difficult membrane protein targets in peer-reviewed journals would be advantageous.
This is an exceptional opportunity to participate in pioneering science with an industry-leading drug discovery company.
The successful candidate is expected to:
The preferred candidate will have the following:
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.
Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please apply through our on-line jobs’ portal with your application in pdf format, quoting reference number 2021-RS-1BMS.
The closing date for applications is 31st December 2021.
Sosei Heptares does not accept speculative or unsolicited CVs from agencies. All speculative or unsolicited CVs submitted without an agreement in place will be considered Sosei Heptares' property and will not obligate us to pay a referral fee.